title: Combination therapy in pulmonary arterial hypertension.
abstract: Many potential therapeutic options are now available for patients with pulmonary arterial hypertension. Interest has emerged in using therapies in various combinations. Retrospective experience has suggested that this approach is common and can be efficacious. Data are emerging supporting the benefit of combination therapy; however, limitations and questions remain about this strategy. This report reviewed the rationale for combination therapy and summarized the results from clinical trials.
authors.affiliation: Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. RChannick@Partners.org
authors.forename: Richard N
authors.initials: RN
authors.lastname: Channick
mesh_terms: D000077300:Bosentan; D004359:Drug Therapy, Combination; D065128:Endothelin Receptor Antagonists; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D065128:Endothelin Receptor Antagonists; D058986:Phosphodiesterase 5 Inhibitors; D011453:Prostaglandins; D013449:Sulfonamides; D014665:Vasodilator Agents; D000077300:Bosentan